Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2023

Feb 2023| TBR1173E| TBRC (Publisher)

Report Highlights

Including: 1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description:
Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab and etanercept biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Units considered $ Billion
Segments covered By Product, By Application, By Distribution Channel
Industry covered Pharmaceuticals
Regions covered Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Companies studied
  • Zydus Cadila
  • Glenmark pharmaceuticals
  • Sandoz (Novartis)
  • Samsung Bioepis
  • Abbvie
  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • Pfizer
  • Hetero Drugs Ltd.
  • Mylan
  • Cipla Ltd.
  • Emcure Pharmaceuticals Ltd.

Scope

Markets Covered:

  • By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
  • By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
  • By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

  • Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8 : Asia-Pacific, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9 : China, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10 : India, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11 : Japan, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12 : Australia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13 : Indonesia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14 : South Korea, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15 : Western Europe, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16 : UK, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17 : Germany, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18 : France, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19 : Eastern Europe, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20 : Russia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21 : North America, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22 : USA, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23 : South America, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24 : Brazil, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25 : Middle East, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26 : Africa, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27 : Zydus Cadila Financial Performance
  • Table 28 : Sandoz (Novartis) Financial Performance
  • Table 29 : Samsung Bioepis Financial Performance
  • Table 30 : Abbvie Financial Performance
  • Table 31 : Amgen Financial Performance
  • Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7 : Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8 : Asia-Pacific, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9 : China, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10 : India, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11 : Japan, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12 : Australia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13 : Indonesia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14 : South Korea, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15 : Western Europe, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16 : UK, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17 : Germany, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18 : France, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19 : Eastern Europe, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20 : Russia, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21 : North America, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22 : USA, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23 : South America, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24 : Brazil, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25 : Middle East, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26 : Africa, Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27 : Zydus Cadila Financial Performance
  • Figure 28 : Sandoz (Novartis) Financial Performance
  • Figure 29 : Samsung Bioepis Financial Performance
  • Figure 30 : Abbvie Financial Performance
  • Figure 31 : Amgen Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031

  • Date - Nov 2022
  • Code - TBR1173D

Including: 1) By Product: Adalimumab Biosimilars; Infliximab Biosimilars; Cipleumab
2) By Application: Crohn’s Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion

Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031 from The Business Research Company ...

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2022

  • Date - Mar 2022
  • Code - TBR1173C

Including: 1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen; Boehringer Ingelheim; ...

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

  • Date - Sep 2021
  • Code - TBR1173B

Including: 1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Adalimumab, Infliximab ...

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change

  • Date - Dec 2020
  • Code - TBR1173A

Including: 1) By Product: Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others); Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)

2) By Application: Crohn’s disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis; Ankylosing spondylitis; Plaque psoriasis; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Covering: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Adalimumab, Infliximab and Etanercept ...

The Business Research Company
Price: $5000

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.